Systematic Review: Theurapeutic Response of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors in Dyslipidaemia Ariq Ratya Satwika (a), Nur Hafidha Hikmayani (b), Ratih Puspita Febrinasari (b)
a) Student of the Faculty of Medicine Universitas Sebelas Maret Surakarta
b) Departement of Pharmacology Faculty of Medicine Universitas Sebelas Maret Surakarta
Abstract
Dyslipidaemia is associated with cardiovascular disease. Statins remain the first choice for dyslipidaemia, however, certain patients will have to consider alternative therapies due to resistance and intolerance. Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors are some of the newer non-statin medications. This systematic review aimed to understand the effects of PCSK9 inhibitors on LDL-C and other lipid parameters in dyslipidaemia management.
A comprehensive search was conducted in PubMed, ScienceDirect, and Cochrane Library for original articles, in English, phase 3 randomized clinical trials, designed to assess the effects of PCSK9 inhibitors on LDL-C and other lipid parameters, published in 2012-2022. The systematic review was performed based on PRISMA guidelines. Jadad score was used for critical appraisal. Data were extracted manually and results were presented in a tabulation format as well as descriptive graphs, to summarize into a conclusion
Nine studies included in this review reported PCSK9 inhibitors improved LDL-C and other lipid parameters. Evolocumab treatment led to 55-67% LDL-C reduction from baseline, while alirocumab led to 45-54% LDL-C reduction from baseline. Both with 41-73% LDL-C achievement <70 mg/dl. Results also showed favourable effects on other lipid parameters.
PCSK9 inhibitors treatment leads to the improvement of LDL-C and other lipid parameters.
